Table 4 Analyses of risk factors between CMV infection and non-CMV infection
Indicator | CMV infection (n = 64) | Non-CMV infection (n = 51) | Pa |
|---|---|---|---|
Disease extent | Â | Â | 0.050 |
 E1 | 1 (1.6%) | 1 (2.0%) |  |
 E2 | 10 (16.1%) | 17 (34.0%) |  |
 E3 | 51 (82.3%) | 32 (64.0%) |  |
Disease severity | Â | Â | 0.003 |
 Mild | 6 (9.7%) | 8 (15.7%) |  |
 Moderate | 18 (29.0%) | 28 (54.9%) |  |
 Severe | 38 (61.3%) | 15 (29.4%) |  |
Disease type | Â | Â | 0.008 |
 Initial onset type | 19 (30.6%) | 5 (9.8%) |  |
 Chronic recurrence type | 43 (69.3%) | 46 (90.2%) |  |
Immunosuppressive agents | Â | Â | 0.042 |
 Yes | 12 (18.8%) | 3 (5.9%) |  |
 No | 52 (81.2%) | 48 (94.1%) |  |
steroid | Â | Â | <0.001 |
 No | 11 (17.2%) | 33 (64.7%) |  |
 Small dose | 6 (9.4%) | 12 (23.5%) |  |
 Moderate dose | 6 (9.4%) | 2 (3.9%) |  |
 Large dose | 41 (64.1%) | 4 (7.8%) |  |
IFX | Â | Â | 0.092 |
 Yes | 4 (6.3%) | 0 |  |
 No | 60 (93.7%) | 51 (100%) |  |
5-ASA | Â | Â | 0.905 |
 Yes | 56 (87.5%) | 45 (88.2%) |  |
 No | 8 (12.5%) | 6 (11.8%) |  |